Ignyta Inc. (RXDX) 6.91 $RXDX
Ignyta's entrectinib an Orphan Drug for subset of NSCLC
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 7:46AM CST
RXDX: 6.91 (+0.06)
Ignyta Receives Orphan Drug Designation from FDA for Entrectinib for the Treatment of Molecularly Defined Subsets of Non-Small Cell Lung Cancer
Business Wire - Thu Feb 05, 6:01AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Ignyta's lead product candidate entrectinib for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC).
RXDX: 6.91 (+0.06)
Ignyta to Present at 2015 Leerink Global Healthcare Conference
Business Wire - Wed Feb 04, 3:00PM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Jonathan Lim, M.D., its President and Chief Executive Officer, and Jacob Chacko, M.D., its Chief Financial Officer, will be making a company presentation at the 2015 Leerink Global Healthcare Conference on February 11, 2015 at 8:25 a.m. Eastern time (5:25 a.m. Pacific time) in New York, NY.
RXDX: 6.91 (+0.06)
Ignyta Expands Clinical Leadership Team with Appointments of Pratik Multani, M.D., M.S., as Chief Medical Officer and Adrian Senderowicz, M.D., as Clinical and Regulatory Strategy Officer
Business Wire - Mon Feb 02, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Pratik S. Multani, M.D., M.S., has been appointed as Chief Medical Officer, assuming responsibility for the role from Adrian Senderowicz, M.D., who has been appointed to the newly-created role of Clinical and Regulatory Strategy Officer.
RXDX: 6.91 (+0.06)
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 15, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
RXDX: 6.91 (+0.06), NVAX: 8.80 (+0.40), ADHD: 6.92 (+0.73), AEGR: 25.15 (+0.88), NVC.TO: 11.27 (-0.23), NVCN: 9.08 (-0.17)
Diarrhea Market Analysis 2014-2015 - Global API Manufacturers and Phase III Pipeline Assessment
M2 - Tue Jan 13, 9:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/4lz259/diarrhea_market) has announced the addition of the "Diarrhea Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Diarrhea- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Salix Pharmaceuticals Ltd. - Novartis AG - Optimer Pharmaceuticals, Inc. - Pfizer Inc. - Prasco Laboratories - ViroPharma Incorporated - Romark Laboratories, L.C. - Parke-Davis - Shire Laboratories, Inc. - Prometheus Laboratories Inc. - Abbott Laboratories - Johnson & Johnson - McNeil Consumer Healthcare - GlaxoSmithKline plc - Valeant Pharmaceuticals International, Inc. - Banner Pharmacaps, Inc. - Mallinckrodt plc - Mutual Pharmaceutical Company, Inc. - Heather Drug Inc. - Sandoz Inc. - Watson Laboratories - Biocodex, Inc. For more information visit http://www.researchandmarkets.com/research/4l...hea_market
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), RXDX: 6.91 (+0.06), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), GSK: 47.94 (+1.99), VRX.TO: 207.95 (-1.47), NVS: 102.20 (-0.17)
Ignyta to Participate in Life Sciences Panel Discussions with Other Thought Leaders at the 2015 East/West CEO Conference
Business Wire - Tue Jan 06, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its Chairman and CEO, Jonathan Lim, M.D., and its Chief Scientific Officer and Senior Vice President, Research, Robert Wild, Ph.D., have been invited to participate in panel discussions relating to trends and innovation in the life sciences industry at the 2015 East/West CEO Conference on January 11, 2015 in San Francisco, CA.
RXDX: 6.91 (+0.06)
Ignyta's Lead Oncology Candidate Gets Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 2:20PM CST
Ignyta, Inc.'s (RXDX) lead candidate, entrectinib (RXDX-101), received orphan drug status and rare pediatric disease designation from the FDA for neuroblastoma.
BIIB: 391.66 (-0.45), RXDX: 6.91 (+0.06), MDCO: 29.79 (+0.91), RGDO: 1.17 (+0.02)
On Winning Track: Complementary Research on Vertex, Ignyta, Novartis, Boeing and TransCanada
PR Newswire - Tue Dec 30, 8:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Vertex (NASDAQ: VRTX), Ignyta (NASDAQ: RXDX), Novartis (NYSE: NVS), Boeing (NYSE: BA), and TransCanada (NYSE: TRP). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
VRTX: 113.66 (+4.03), RXDX: 6.91 (+0.06), TRP: 45.94 (-0.81), BA: 149.73 (+1.64), NVS: 102.20 (-0.17)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 8:13AM CST
PT: 0.83 (+0.04), RXDX: 6.91 (+0.06), ARTX: 2.44 (+0.06), NBG: 1.61 (+0.18), JOB: 0.79 (+0.01), LIVE: 3.23 (-0.22), MTW: 21.86 (+0.34)
Ignyta neuroblastoma drug candidate tagged an Orphan Drug
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 6:33AM CST
RXDX: 6.91 (+0.06)
Ignyta Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA for Entrectinib for the Treatment of Neuroblastoma
Business Wire - Mon Dec 29, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted both orphan drug designation and rare pediatric disease designation for Ignyta's lead product candidate entrectinib for the treatment of neuroblastoma.
RXDX: 6.91 (+0.06)
Ignyta revises terms of entrectinib license agreement with Nerviano
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 8:40AM CST
RXDX: 6.91 (+0.06)
Ignyta Announces Amendment to License Agreement with Nerviano
Business Wire - Mon Dec 15, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that it has entered into an amendment to its license agreement with Nerviano Medical Sciences, S.r.l. relating to its entrectinib (formerly RXDX-101) product candidate. The amendment modifies the milestones that would trigger the initial three milestone payments specified in the license agreement. Pursuant to the amendment, the initial milestone payment of $10 million will be due and payable to Nerviano by December 31, 2014, and the second and third milestone payments will be triggered by revised clinical and/or regulatory events relating to entrectinib or other licensed products. The amounts of such milestone payments have not changed.
RXDX: 6.91 (+0.06)
Ignyta Receives Approval of Nonproprietary Name Entrectinib for Lead Product Candidate, RXDX-101
Business Wire - Tue Dec 09, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) "entrectinib" for the company's lead product candidate, RXDX-101. INNs facilitate the identification of active pharmaceutical ingredients, and each INN is a globally recognized unique name.
RXDX: 6.91 (+0.06)
Ignyta Announces CLIA Certification Achieved by its Diagnostic Laboratory
Business Wire - Tue Dec 02, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its San Diego diagnostic laboratory successfully passed the State of California survey for CLIA (Clinical Laboratory Improvement Amendments) certification. The State of California inspector granted Ignyta permission to begin offering molecular diagnostic services to patients, including those in the company's clinical trials.
RXDX: 6.91 (+0.06)
Ignyta to Present at Upcoming Investor Conferences
Business Wire - Tue Nov 25, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that its management will be making company presentations at the following investor conferences in December 2014:
RXDX: 6.91 (+0.06)
Ignyta Announces RXDX-101 Presentations at the 2014 EORTC-NCI-AACR 'Molecular Targets and Cancer Therapeutics' Conference
Business Wire - Tue Nov 18, 3:00PM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the acceptance of two abstracts for poster presentations relating to RXDX-101, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The poster presentations will be held on November 20-21, 2014 in Barcelona, Spain.
RXDX: 6.91 (+0.06)
Ignyta's (RXDX) CEO Jonathan Lim on Q3 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 6:06PM CST
RXDX: 6.91 (+0.06)
Ignyta posts 3Q loss
Automated Insights - Fri Nov 07, 3:07PM CST
SAN DIEGO (AP) _ Ignyta Inc. (RXDX) on Friday reported a loss of $10.7 million, or 55 cents per share, in its third quarter.
RXDX: 6.91 (+0.06)
Ignyta's entrectinib an Orphan Drug for subset of NSCLC
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 7:46AM CST
RXDX: 6.91 (+0.06)
Ignyta Receives Orphan Drug Designation from FDA for Entrectinib for the Treatment of Molecularly Defined Subsets of Non-Small Cell Lung Cancer
Business Wire - Thu Feb 05, 6:01AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Ignyta's lead product candidate entrectinib for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC).
RXDX: 6.91 (+0.06)
Ignyta to Present at 2015 Leerink Global Healthcare Conference
Business Wire - Wed Feb 04, 3:00PM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Jonathan Lim, M.D., its President and Chief Executive Officer, and Jacob Chacko, M.D., its Chief Financial Officer, will be making a company presentation at the 2015 Leerink Global Healthcare Conference on February 11, 2015 at 8:25 a.m. Eastern time (5:25 a.m. Pacific time) in New York, NY.
RXDX: 6.91 (+0.06)
Ignyta Expands Clinical Leadership Team with Appointments of Pratik Multani, M.D., M.S., as Chief Medical Officer and Adrian Senderowicz, M.D., as Clinical and Regulatory Strategy Officer
Business Wire - Mon Feb 02, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Pratik S. Multani, M.D., M.S., has been appointed as Chief Medical Officer, assuming responsibility for the role from Adrian Senderowicz, M.D., who has been appointed to the newly-created role of Clinical and Regulatory Strategy Officer.
RXDX: 6.91 (+0.06)
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 15, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
RXDX: 6.91 (+0.06), NVAX: 8.80 (+0.40), ADHD: 6.92 (+0.73), AEGR: 25.15 (+0.88), NVC.TO: 11.27 (-0.23), NVCN: 9.08 (-0.17)
Diarrhea Market Analysis 2014-2015 - Global API Manufacturers and Phase III Pipeline Assessment
M2 - Tue Jan 13, 9:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/4lz259/diarrhea_market) has announced the addition of the "Diarrhea Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Diarrhea- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Salix Pharmaceuticals Ltd. - Novartis AG - Optimer Pharmaceuticals, Inc. - Pfizer Inc. - Prasco Laboratories - ViroPharma Incorporated - Romark Laboratories, L.C. - Parke-Davis - Shire Laboratories, Inc. - Prometheus Laboratories Inc. - Abbott Laboratories - Johnson & Johnson - McNeil Consumer Healthcare - GlaxoSmithKline plc - Valeant Pharmaceuticals International, Inc. - Banner Pharmacaps, Inc. - Mallinckrodt plc - Mutual Pharmaceutical Company, Inc. - Heather Drug Inc. - Sandoz Inc. - Watson Laboratories - Biocodex, Inc. For more information visit http://www.researchandmarkets.com/research/4l...hea_market
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), RXDX: 6.91 (+0.06), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), GSK: 47.94 (+1.99), VRX.TO: 207.95 (-1.47), NVS: 102.20 (-0.17)
Ignyta to Participate in Life Sciences Panel Discussions with Other Thought Leaders at the 2015 East/West CEO Conference
Business Wire - Tue Jan 06, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its Chairman and CEO, Jonathan Lim, M.D., and its Chief Scientific Officer and Senior Vice President, Research, Robert Wild, Ph.D., have been invited to participate in panel discussions relating to trends and innovation in the life sciences industry at the 2015 East/West CEO Conference on January 11, 2015 in San Francisco, CA.
RXDX: 6.91 (+0.06)
Ignyta's Lead Oncology Candidate Gets Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 2:20PM CST
Ignyta, Inc.'s (RXDX) lead candidate, entrectinib (RXDX-101), received orphan drug status and rare pediatric disease designation from the FDA for neuroblastoma.
BIIB: 391.66 (-0.45), RXDX: 6.91 (+0.06), MDCO: 29.79 (+0.91), RGDO: 1.17 (+0.02)
On Winning Track: Complementary Research on Vertex, Ignyta, Novartis, Boeing and TransCanada
PR Newswire - Tue Dec 30, 8:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Vertex (NASDAQ: VRTX), Ignyta (NASDAQ: RXDX), Novartis (NYSE: NVS), Boeing (NYSE: BA), and TransCanada (NYSE: TRP). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
VRTX: 113.66 (+4.03), RXDX: 6.91 (+0.06), TRP: 45.94 (-0.81), BA: 149.73 (+1.64), NVS: 102.20 (-0.17)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 8:13AM CST
PT: 0.83 (+0.04), RXDX: 6.91 (+0.06), ARTX: 2.44 (+0.06), NBG: 1.61 (+0.18), JOB: 0.79 (+0.01), LIVE: 3.23 (-0.22), MTW: 21.86 (+0.34)
Ignyta neuroblastoma drug candidate tagged an Orphan Drug
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 6:33AM CST
RXDX: 6.91 (+0.06)
Ignyta Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA for Entrectinib for the Treatment of Neuroblastoma
Business Wire - Mon Dec 29, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted both orphan drug designation and rare pediatric disease designation for Ignyta's lead product candidate entrectinib for the treatment of neuroblastoma.
RXDX: 6.91 (+0.06)
Ignyta revises terms of entrectinib license agreement with Nerviano
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 8:40AM CST
RXDX: 6.91 (+0.06)
Ignyta Announces Amendment to License Agreement with Nerviano
Business Wire - Mon Dec 15, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that it has entered into an amendment to its license agreement with Nerviano Medical Sciences, S.r.l. relating to its entrectinib (formerly RXDX-101) product candidate. The amendment modifies the milestones that would trigger the initial three milestone payments specified in the license agreement. Pursuant to the amendment, the initial milestone payment of $10 million will be due and payable to Nerviano by December 31, 2014, and the second and third milestone payments will be triggered by revised clinical and/or regulatory events relating to entrectinib or other licensed products. The amounts of such milestone payments have not changed.
RXDX: 6.91 (+0.06)
Ignyta Receives Approval of Nonproprietary Name Entrectinib for Lead Product Candidate, RXDX-101
Business Wire - Tue Dec 09, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) "entrectinib" for the company's lead product candidate, RXDX-101. INNs facilitate the identification of active pharmaceutical ingredients, and each INN is a globally recognized unique name.
RXDX: 6.91 (+0.06)
Ignyta Announces CLIA Certification Achieved by its Diagnostic Laboratory
Business Wire - Tue Dec 02, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its San Diego diagnostic laboratory successfully passed the State of California survey for CLIA (Clinical Laboratory Improvement Amendments) certification. The State of California inspector granted Ignyta permission to begin offering molecular diagnostic services to patients, including those in the company's clinical trials.
RXDX: 6.91 (+0.06)
Ignyta to Present at Upcoming Investor Conferences
Business Wire - Tue Nov 25, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that its management will be making company presentations at the following investor conferences in December 2014:
RXDX: 6.91 (+0.06)
Ignyta Announces RXDX-101 Presentations at the 2014 EORTC-NCI-AACR 'Molecular Targets and Cancer Therapeutics' Conference
Business Wire - Tue Nov 18, 3:00PM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the acceptance of two abstracts for poster presentations relating to RXDX-101, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The poster presentations will be held on November 20-21, 2014 in Barcelona, Spain.
RXDX: 6.91 (+0.06)
Ignyta's (RXDX) CEO Jonathan Lim on Q3 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 6:06PM CST
RXDX: 6.91 (+0.06)
Ignyta posts 3Q loss
Automated Insights - Fri Nov 07, 3:07PM CST
SAN DIEGO (AP) _ Ignyta Inc. (RXDX) on Friday reported a loss of $10.7 million, or 55 cents per share, in its third quarter.
RXDX: 6.91 (+0.06)
